A substance used to treat or prevent parasitic infections.
| Member | Definition | Class |
|---|
| 4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol | A terpineol that is 1-menthene carrying a hydroxy substituent at position 4. | 4-terpineol |
| anisomycin | An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. | (-)-anisomycin |
| annomontine | An alkaloid that is beta-carboline substituted at position C-1 by a 2-aminopyrimidin-4-yl moiety. An antiparasitic agent found in Annona montana and Annona foteida. | annomontine |
| aureothin | A C-nitro compound that is (3Z)-3-[(2E)-2-methyl-3-(4-nitrophenyl)prop-2-en-1-ylidene]tetrahydrofuran which is substituted by a 6-methoxy-3,5-dimethyl-4-oxo-4H-pyran-2-yl group at position 5. It is isolated from the soil bacterium, Streptomyces thioluteus and exhibits antitumor, antifungal, and insecticidal activities. | aureothin |
| benzoylmetronidazole | A benzoate ester resulting from the formal condensation of benzoic acid with the hydroxy group of metronidazole. | metronidazole benzoate |
| costunolide | A germacranolide with anthelminthic, antiparasitic and antiviral activities. | costunolide |
| cycloguanil | A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil. | cycloguanil |
| diaveridine | An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species. | diaveridine |
| dimetridazole | A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by methyl groups. An antiprotozoal drug, it has been banned by both the Government of Canada and the European Union as a livestock feed additive owing to suspicions of it being carcinogenic. | dimetridazole |
| diminazene | A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group. | diminazene |
| diminazene aceturate | An N-acetylglycinate salt resulting from the reaction of diminazene with 2 mol eq. of N-acetylglycine. | diminazene diaceturate |
| e 64 | | E64 zwitterion; E64 |
| erysodine | An erythrina alkaloid with formula C18H21NO3 isolated from several erythrina plant species. It is a competitive antagonist of nicotinic acetylcholine receptors and exhibits antiparasitic and insecticidal activities. | erysodine |
| leflunomide | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide. | leflunomide |
| metronidazole | A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. | metronidazole |
| niclosamide | A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections. | niclosamide |
| paromomycin | An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. | paromomycin |
| ronidazole | A carbamate ester that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by methyl and (carbamoyloxy)methyl groups, respectively. An antiprotozoal agent, it is used in veterinary medicine for the treatment of histomoniasis and swine dysentery. | ronidazole |
| tinidazole | 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. | tinidazole |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 67.9K protein | Vaccinia virus | Potency | 1.1322 | 2 | 4 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 48.5088 | 1 | 2 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 31.5153 | 2 | 4 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.8715 | 1 | 4 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 8.1062 | 1 | 4 |
| AR protein | Homo sapiens (human) | Potency | 8.1114 | 10 | 27 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 3.6282 | 3 | 9 |
| arylsulfatase A | Homo sapiens (human) | Potency | 37.9330 | 1 | 2 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 3.8429 | 10 | 14 |
| Ataxin-2 | Homo sapiens (human) | Potency | 4.6875 | 1 | 4 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 4.4257 | 2 | 6 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 0.9528 | 1 | 1 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 1.3092 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 24.0682 | 2 | 4 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 1.8058 | 1 | 2 |
| caspase-3 | Homo sapiens (human) | Potency | 1.8058 | 1 | 2 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 9.3422 | 3 | 8 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 5.0816 | 2 | 9 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 5.6234 | 1 | 1 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 5.6234 | 1 | 1 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 28.1838 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0398 | 1 | 1 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.0398 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 1 | 2 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 8.1235 | 1 | 2 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 11.5886 | 1 | 3 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 9.2876 | 1 | 2 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 18.9979 | 1 | 2 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 5.4332 | 2 | 10 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 4.1198 | 1 | 2 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 1.8602 | 1 | 4 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 0.3445 | 2 | 2 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 2.0749 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 54.7876 | 1 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 29.9349 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 11.2202 | 1 | 1 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 17.7828 | 1 | 1 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 17.7828 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 7.2492 | 9 | 31 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 17.3427 | 2 | 4 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.7135 | 10 | 34 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 5.5528 | 1 | 2 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 11.1715 | 4 | 9 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 11.3132 | 4 | 6 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 4.2284 | 1 | 1 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 6.0880 | 1 | 3 |
| G | Vesicular stomatitis virus | Potency | 9.2876 | 1 | 2 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| GALC protein | Homo sapiens (human) | Potency | 0.5120 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 5.4332 | 1 | 5 |
| geminin | Homo sapiens (human) | Potency | 3.1755 | 4 | 13 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 11.3761 | 3 | 10 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.8552 | 1 | 2 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 2.1784 | 2 | 4 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 4.5374 | 1 | 4 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 1.9953 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 1.8493 | 1 | 1 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 17.5038 | 2 | 5 |
| hepatitis C virus polyprotein | | Potency | 7.0456 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 9.5104 | 2 | 11 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 1.2460 | 2 | 8 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 130.6660 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 9.2876 | 1 | 2 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 9.5892 | 3 | 4 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 61.6448 | 1 | 2 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 2.2536 | 2 | 4 |
| IDH1 | Homo sapiens (human) | Potency | 4.9978 | 1 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 9.2876 | 1 | 4 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 5.0630 | 1 | 4 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 5.0630 | 1 | 4 |
| Interferon beta | Homo sapiens (human) | Potency | 15.8755 | 3 | 6 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 2.9476 | 2 | 10 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 0.3762 | 1 | 2 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 11.1662 | 4 | 9 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 79.4328 | 1 | 1 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 5.1209 | 1 | 2 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 8.4209 | 2 | 3 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 10.2782 | 2 | 4 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 37.4528 | 1 | 5 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 0.0794 | 1 | 1 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 14.6945 | 1 | 3 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.6257 | 1 | 4 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 14.8617 | 3 | 7 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 3.1611 | 2 | 3 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 54.9410 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 11.4964 | 2 | 7 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 7.6006 | 1 | 2 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 1.4177 | 3 | 11 |
| Ornithine decarboxylase | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1 | 1 |
| P53 | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 0.7667 | 1 | 1 |
| Parkin | Homo sapiens (human) | Potency | 1.6337 | 2 | 3 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 11.5080 | 2 | 5 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 19.1562 | 1 | 2 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 1.1884 | 2 | 3 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 9.9929 | 4 | 7 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 39.8107 | 1 | 1 |
| PINK1 | Homo sapiens (human) | Potency | 1.6326 | 1 | 2 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 6.2303 | 1 | 2 |
| polyprotein | Zika virus | Potency | 6.0880 | 1 | 3 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 0.1585 | 1 | 1 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| PPM1D protein | Homo sapiens (human) | Potency | 18.5569 | 1 | 2 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 14.3442 | 2 | 6 |
| progesterone receptor | Homo sapiens (human) | Potency | 30.8960 | 1 | 3 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 10.1474 | 4 | 4 |
| pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 3.1623 | 2 | 2 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 79.4328 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 7.3708 | 2 | 9 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.5807 | 1 | 4 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 16.8336 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 10.8516 | 3 | 16 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 17.1689 | 4 | 8 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 1.6208 | 2 | 2 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 1.4972 | 2 | 4 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 1.4972 | 2 | 4 |
| Smad3 | Homo sapiens (human) | Potency | 0.1365 | 4 | 4 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 1.6743 | 2 | 3 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 9.2837 | 2 | 12 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 21.0316 | 1 | 4 |
| TDP1 protein | Homo sapiens (human) | Potency | 7.6941 | 2 | 18 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 13.4823 | 1 | 3 |
| Thrombopoietin | Homo sapiens (human) | Potency | 4.0216 | 2 | 4 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 2.3747 | 2 | 8 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 17.7201 | 2 | 3 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 5.7834 | 2 | 6 |
| TSHR protein | Homo sapiens (human) | Potency | 92.5374 | 2 | 3 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 6.2303 | 1 | 2 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 6.2303 | 1 | 2 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 42.5559 | 1 | 3 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 57.1756 | 2 | 3 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 11.2460 | 4 | 9 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 63.0957 | 1 | 1 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 4.5374 | 1 | 4 |